Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Production / Operations

Optimi Health exports psilocybin capsules to Australia

By The Northwire Desk — AI Analysis Feb 19, 2026 · 13:48 OPTI · 0.375 Optimi Health Corp
OPTI · Price

Executive Summary

  • Optimi Health Corp. has successfully exported its GMP-manufactured, natural five-milligram psilocybin capsules to Australia for the treatment of patients with treatment-resistant depression (TRD).
  • This shipment marks the company's second finished drug product supplied into Australia's Authorised Prescriber Scheme, following its MDMA capsules for PTSD.
  • The distribution occurs under a nationally regulated framework where the Department of Veterans' Affairs (DVA) may reimburse eligible patients for the full cost of psychedelic-assisted therapy.

Key Details

  • Product Exported: GMP-manufactured natural five-milligram psilocybin capsules.
  • Indication: Treatment-resistant depression (TRD).
  • Regulatory Framework: Australia's Authorised Prescriber Scheme.
  • Significance: Second finished drug product supplied to the Australian market; first was 40mg and 60mg MDMA capsules for PTSD.
  • Manufacturing: Produced under a Health Canada-issued drug establishment licence; includes cultivation, extraction, encapsulation, and packaging via proprietary GMP process.
  • Data Collection: Treatment outcomes are being captured through Australia's national patient registry in partnership with the Australian National University (ANU).
  • Reimbursement: The Department of Veterans' Affairs (DVA) may reimburse eligible patients for the full cost of the medicine and associated psychotherapy.
  • Access Information: Clinicians and authorized programs can seek access information through Mind Medicine Australia.

Notable Quotes

  • "Optimi's five-milligram naturally derived psilocybin capsules are now available to patients in Australia suffering from treatment-resistant depression... Supplying pharmaceutical-grade psilocybin outside of traditional clinical trials within a nationally regulated framework is an important milestone for our team and shareholders." — Dane Stevens, CEO and Co-founder
Read the original news release →

More from Optimi Health Corp

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory